{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:36:44Z","timestamp":1790779004021,"version":"4.1.0"},"reference-count":15,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.3201\/eid2409.180233","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T15:23:11Z","timestamp":1528471391000},"page":"1696-1699","source":"Crossref","is-referenced-by-count":108,"title":["Use of Favipiravir to Treat Lassa Virus Infection in Macaques"],"prefix":"10.3201","volume":"24","author":[{"given":"Kyle","family":"Rosenke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna B.","family":"Westover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick William","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Martellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Saturday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Lovaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana P.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Komeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Safronetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2409.180233-201808141053-R1","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3390\/v4102031","article-title":"Pathogenesis of Lassa fever.","volume":"4","author":"Yun","year":"2012","journal-title":"Viruses"},{"key":"key-10.3201\/eid2409.180233-201808141053-R2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1863-2378.2012.01469.x","article-title":"Lassa fever in West Africa: evidence for an expanded region of endemicity.","volume":"59","author":"Sogoba","year":"2012","journal-title":"Zoonoses Public Health"},{"key":"key-10.3201\/eid2409.180233-201808141053-R3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1086\/657315","article-title":"Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.","volume":"51","author":"Bausch","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2409.180233-201808141053-R4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor.","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid2409.180233-201808141053-R5","doi-asserted-by":"publisher","first-page":"14775","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci Rep"},{"key":"key-10.3201\/eid2409.180233-201808141053-R6","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/infdis\/jiv522","article-title":"Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever.","volume":"213","author":"Oestereich","year":"2016","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid2409.180233-201808141053-R7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1743-422X-8-205","article-title":"Pathogenesis of Lassa fever in cynomolgus macaques.","volume":"8","author":"Hensley","year":"2011","journal-title":"Virol J"},{"key":"key-10.3201\/eid2409.180233-201808141053-R8","unstructured":"World Health Organization. Weekly bulletin on outbreaks and other emergencies [cited 2018 Feb 5]. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260122\/OEW5-2701222018.pdf;jsessionid=D19D5C05BE101587B3AC601D56544764?sequence=1"},{"key":"key-10.3201\/eid2409.180233-201808141053-R9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/cid\/cix406","article-title":"Emory Serious Communicable Diseases Unit. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever.","volume":"65","author":"Raabe","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2409.180233-201808141053-R10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/infdis\/141.5.580","article-title":"Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.","volume":"141","author":"Jahrling","year":"1980","journal-title":"J Infect Dis"},{"key":"key-10.3201\/eid2409.180233-201808141053-R11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin.","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2409.180233-201808141053-R12","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.3201\/eid1612.100994","article-title":"Ribavirin for Lassa fever postexposure prophylaxis.","volume":"16","author":"Hadi","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid2409.180233-201808141053-R13","doi-asserted-by":"publisher","first-page":"e1001967","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea.","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid2409.180233-201808141053-R14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","article-title":"Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.","volume":"126","author":"Westover","year":"2016","journal-title":"Antiviral Res"},{"key":"key-10.3201\/eid2409.180233-201808141053-R15","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.","volume":"23","author":"Mire","year":"2017","journal-title":"Nat Med"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/24\/9\/18-0233_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:25:10Z","timestamp":1732987510000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/24\/9\/18-0233_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2409.180233","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}